SEC Form SC 13G filed by ASLAN Pharmaceuticals Limited

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
	SCHEDULE 13G
	Under the Securities Exchange Act of 1934
	(Amendment No.   )*
	ASLAN Pharmaceuticals Limited
	(Name of Issuer)

	Ordinary Shares, par value $0.01 per share
	(Title of Class of Securities)

	04522R200
	(CUSIP Number)

	March 14, 2024
	(Date of Event which Requires Filing of this Statement)

[ ]	Rule 13d-1(b)

[x]	Rule 13d-1(c)

[ ]	Rule 13d-1(d)

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Lind Global Fund II LP
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)            [ ]
	(b)            [x]
3	SEC Use Only
4	Citizenship or Place of Organization.   Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5  Sole Voting Power 1,250,000
		6  Shared Voting Power   0
		7  Sole Dispositive Power   1,250,000
		8  Shared Dispositive Power   0
9	Aggregate Amount Beneficially Owned by Each Reporting Person   1,250,000(1)
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11	Percent of Class Represented by Amount in Row (9)*   5.7%(2)
12	Type of Reporting Person (See Instructions) PN

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only) Lind Global Partners II LLC
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)            [ ]
	(b)            [x]
3	SEC Use Only
4	Citizenship or Place of Organization.   Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5  Sole Voting Power   1,250,000
		6  Shared Voting Power   0
		7  Sole Dispositive Power   1,250,000
		8  Shared Dispositive Power   0
9	Aggregate Amount Beneficially Owned by Each Reporting Person   1,250,000(1)
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11	Percent of Class Represented by Amount in Row (9)*   5.7%(2)
12	Type of Reporting Person (See Instructions) OO

1	Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)   Jeff Easton
2	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)            [ ]
	(b)            [x]
3	SEC Use Only
4	Citizenship or Place of Organization.   United States
Number of Shares Beneficially Owned by Each Reporting Person With		5  Sole Voting Power   1,250,000
		6  Shared Voting Power   0
		7  Sole Dispositive Power   1,250,000
		8  Shared Dispositive Power   0
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,250,000(1)
10	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11	Percent of Class Represented by Amount in Row (9)*   5.7%(2)
12	Type of Reporting Person (See Instructions)   IN

	(a)	Name of Issuer
		ASLAN Pharmaceuticals Limited
	(b)	Address of Issuer’s Principal Executive Offices
		3 Temasek Avenue Level 18 Centennial Tower Singapore 039190

	(a)	Name of Person Filing
		This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):   •     Lind Global Fund II LP, a Delaware limited partnership; •     Lind Global Partners II LLC, a Delaware limited liability company; and •     Jeff Easton, an individual and a citizen of the United States of America.   Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.   Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
	(b)	Address of Principal Business Office or, if none, Residence
		The address of the principal business office for each of the Reporting Persons is:   444 Madison Ave, Floor 41 New York, NY 10022
	(c)	Citizenship
		See Row 4 of cover page for each Reporting Person.
	(d)	Title of Class of Securities
		Ordinary Shares, par value $0.01 per share
	(e)	CUSIP Number
		04522R200

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Item 4.

Ownership

	(a)	Amount Beneficially Owned
		See Row 9 of cover page for each Reporting Person.
	(b)	Percent of Class
		See Row 11 of cover page for each Reporting Person.

	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote
			See Row 5 of cover page for each Reporting Person.
		(ii)	shared power to vote or to direct the vote
			See Row 6 of cover page for each Reporting Person.
		(iii)	sole power to dispose or to direct the disposition of
			See Row 7 of cover page for each Reporting Person.
		(iv)	shared power to dispose or to direct the disposition of
			See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of Five Percent or Less of a Class

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Item 8.

Identification and Classification of Members of the Group

Item 9.

Notice of Dissolution of Group

Item 10.

Certification

Exhibits

Exhibit

99.1	Joint Filing Agreement by and among the Reporting Persons.

LIND GLOBAL FUND II LP
By:		Lind Global Partners II LLC
		its General Partner
By:		/s/ Jeff Easton
Name:		Jeff Easton
Title:		Managing Member
LIND GLOBAL PARTNERS II LLC
By:		/s/ Jeff Easton
Name:		Jeff Easton
Title:		Managing Member
JEFF EASTON
By:		/s/ Jeff Easton